GRAPE SEED EXTRACT

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLAs) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.

Notes

Date

August 28, 2018

Proper name(s), Common name(s), Source material(s)

Table 1. Proper name(s), Common name(s), Source material(s)
Proper name(s) Common name(s) Source material(s)
Proper name(s) Part(s)
Grape seed extract Grape seed extract Vitis vinifera Seed

References: Sano et al. 2007; Common name: Sano et al. 2007; Source material: USDA 2018, Sano et al. 2007, Henriet 1993.

Route of Administration

Oral

Dosage Form(s)

This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document.

Acceptable dosage forms for the age category listed in this monograph and specified route of administration are indicated in the Compendium of Monographs Guidance Document.

Use(s) or Purpose(s)

Dose(s)

Subpopulation(s)

Adults 18 years and older

Quantity(ies)

Antioxidant

Methods of preparation: Standardized extracts (Dry extract, Tincture, Fluid extract, Decoction, Infusion)

Not to exceed 475 milligrams of grape seed extract, per day; standardized to 70-85% oligomeric proanthocyanidins (OPC) (Sano et al. 2007; Natella et al. 2002).

Relief of symptoms related to non-complicated CVI

Methods of preparation: Standardized extracts (Dry extract, Tincture, Fluid extract, Decoction, Infusion)

150 - 475 milligrams of grape seed extract, per day; standardized to 80-85% oligomeric proanthocyanidins (OPC) (Sano et al. 2007; Henriet 1993; Henriet 1988; Thébaut et al. 1985; Delacroix 1981; Sarrat 1981)

Direction(s) for use

No statement required.

Duration of Use

All products
Consult a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 3 months (Sano et al. 2007).
Relief of symptoms related to non-complicated CVI
Use for at least 1 month to see beneficial effects (Thébaut et al. 1985; Delacroix 1981; Sarrat 1981).

Risk Information

Caution(s) and Warning(s)

All products
Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding.
Relief of symptoms related to non-complicated CVI
Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

Contraindication(s)

No statement required.

Known Adverse Reaction(s)

No statement required.

Storage Condition(s)

No statement required.

Non Medicinal Ingredients

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

Specifications

References Cited

References reviewed